drugset / Trial / NCT01065662
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
Phase 1
Completed
11 enrolled
Susana M. Campos, MD
AstraZeneca · collabBeth Israel Deaconess Medical Center · collabMassachusetts General Hospital · collabNational Comprehensive Cancer Network · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine the safety of the combination of the two drugs cediranib and temsirolimus and the highest doses of these two drugs that can be given in combination to people safely. Cediranib is a drug that may stop blood supply to the tumor and therefore help keep cancer cells from growing. Temsirolimus is a drug that may stop cancer cells from growing. These drugs have been used in other research studies in ovarian and kidney cancer and these studies suggest that these drugs may help to keep cancer from growing in this research study.
Timeline
- Start
- 2010-02
- Primary completion
- 2013-09
- Completion
- 2021-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cediranib | Small molecule | — | Oral |
| Subject | Temsirolimus | Small molecule | — | — |